Stocktwits Top 25 – Week 35 📈

Good afternoon everyone and welcome to the Stocktwits Top 25 Newsletter for Week 35, 2020. 

The Stocktwits Top 25 reports the top 25 performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. 

Here’s your Stocktwits Top 25 Lists for Week 35:

ST Top 25 S&P 500

19 of the 25 names on the ST Top 25 S&P 500 list closed higher on the week, much better than last week., Inc was the list’s biggest winner, up 30.63%. The stock made its Freshman debut and claimed the #12 on the ST Top 25 S&P 500 list. See more on this below.

Adobe also made its Freshman debut at #21 after gaining 9.2% on the week.

eBay, Inc was the ST Top 25 S&P 500’s biggest loser falling 6.73%. It dropped 10 spots from #14 to #24. 

#1 $CARR and #2 $NVDA gained 2.6% and 3.6% respectively and held their top spots. This race has been tightening in recent weeks.

The Stocktwits Top 25 S&P 500 Momentum Meter closed up 2.94%. This wasn’t enough to beat the full index which gained 3.26%. The differential of -0.32% indicates that the top stocks in the S&P 500 performed about as well as the full index.

The Big Cap Nasdaq 100

The Stocktwits Top 25 Nasdaq 100 was overwhelmingly green, once again. 22 out of the 25 names were positive for the week. Strong like a bull.

eBay, Inc led the losers just like it led the S&P 500 List of losers. It fell 7 spots from #12 to #19.

Netflix jumped 6.5% in Week 35 after trading quietly for over a month. $NFLX is 5% below all-time highs, now up 62% YTD. See more on this below.

$FB jumped 10% higher following the introduction of Facebook Shop. It was one of three Freshmen alongside $WDAY and $MSFT.

$WDAY was the strongest performing Freshmen gaining 26.63% following earnings. Beast.

The ST Top 25 Nasdaq 100 Momentum Meter gained 4.09% for week #35 while the full Nasdaq 100 gained 3.82%. The 0.27% differential suggests the top stocks outperformed the full index but only by a slim margin.

Small-Cap Russell 2000

The ST Top 25 R2K List finally gave it up. It closed lower for the first time in ages. 15 stocks dropped lower for the week, 5 of them falling 20% or more😬

Novavax fell 21.73% and still performed better than #2 Vaxart which dropped 24.33%. Both of these biotechs can be seen on the losers list below.

iBio, Inc. was the ST Top 25 R2K’s best performing name, rising 26.5%. The company announced an exclusive worldwide license agreement for its Covid-19 Vaccine. 

$CZR and $HOME were the only Freshmen. Caesars Entertainment gained 10% but At Home Group fell 3.3%. They rank in at #22 and #25%.

The ST Top 25 R2K List’s Momentum Meter plummeted 4.84% while the full Russell 2000 climbed 1.67%. The 6.51% differential is primarily attributable to the poor performance of the top 5 R2K stocks on the list, all of which fell double digit percentages.

Finally, the leaders are coming back down to earth a bit relative to the broader index.


The ST Top 25 Top Dawg of the Week for Week 35, 2020 is

The cloud-based software company vaulted onto the ST Top 25 S&P 500 List at #12. The stock jumped 30.65% following a killer Q2 earnings report on Tuesday after the market close. 

$CRM leapt 26% on Wednesday. The company saw earnings grow a colossal 118% along with a 29% increase in revenue. $CRM also raised full-year revenue estimates. 😉

Here are the results:

EPS: $1.44 vs $0.67 est.

Revenue: $5.15B vs $4.9B est.

UBS analyst Jennifer Lowe had summed it up:

After a mixed Q1, Salesforce saw a sharp recovery in Q2 with CRPO (current remaining performance obligations), billings, revenue, and cash flow all landing well above Street expectations. We think this strong result highlights the ongoing customer prioritization of digital transformation initiatives, with the Covid-19 pandemic driving even greater urgency to engage customers in new ways. Not only did key top-line measures beat, but margin outperformance and reaffirmation that no M&A is likely near-term should also counter key tenets of the bear case.

$CRM will be added to the Dow Jones Industrial Average, replacing Exxon Mobil.

The stock is now up 66.68% YTD.

The Winners 📈

△  #14 N100 –  Netflix woke up this week. The stock was up 7% and moved from #18 to #14 on the ST Top 25 N100 list. 

Recently, $NFLX was not participating as much in the broad market uptrend the way it was earlier in the year as it didn’t move plus or minus 2.5% or more for the last 5 trading weeks. The dormancy ended this week after shares rocketed 12% higher on Wednesday. $NFLX’s market cap grew more than $25 billion on Wednesday alone.

Here’s the weekly chart visualizing the tight trading range.

And here’s the daily chart, peep Wednesday’s mega candle.

The stock is up 62% YTD.

△ #25 N100 – Facebook kept its strong 2020 performance rollin’ as it rose 10% this week. $FB jumped onto the ST Top 25 N100 list as a freshman ranked at #25.

The stock jumped 3.5% on Tuesday and another 8.25% Wednesday after the company introduced “Facebook Shop”, a new shopping section in Facebook’s main app. This is part of a larger push companies are taking to increase online shopping amid the Covid-19 outbreak.

$FB also announced that Instagram’s Checkout Feature, which allows users to pay for items inside the app will be available to U.S. businesses soon.

$FB is up 43% YTD.

△ #17 R2K – Sunrun was a runnin’ this week. The US based solar provider made new all-time highs rallying 15%. Sunrun has closed green 17 out of the last 23 weeks and is up 512% since its Mar. 20 bottom. What a freak! It climbed 8 spots from #25 to #17 on the ST Top 25 R2K list.

On Aug. 20, $RUN announced a partnership with GRID Alternative (a leader in renewable energy technology) that will supply 100% free battery systems to low-income customers in wildfire-prone areas in the United States. It’s a timely opportunity as blackouts have forced thousands of Californians into darkness.

This offer includes a home battery storage system along with 10 years of monitoring/maintenance on top of original warranties.

Cool stuff this company is doing during an unfortunate situation, keep it up! 💪

Here’s the YTD chart, up 302%.

△ #7 R2K – iBio, Inc made Week #35’s Winners list after it spent the last three weeks on the Sinners list. It was down 62.4% during that time. This week’s 26% return was good enough to move the name up a spot on the ST Top 25 R2K list to #7. 

$IBIO announced that it entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc.

Tom Isett, Chairman & CEO of iBio had this to say:

We see tremendous opportunity in our partnership with Planet to develop this novel immunoadhesin molecule as a potential COVID-19 disease treatment. We believe the molecule may be effective against SARS-CoV-2 infection, and that it has the potential to be rapidly re-designed in the FastPharming® System to address mutations in the current virus, if any, as well as future coronaviral diseases.

$IBIO is up 766% YTD.

The Sinners 📉

▼ #1 R2k – Novavax got hammered for the third week in a row. This week it was down 22%, now down 40% since its Aug. 10 high close…

Despite the rough three weeks, $NVAX is still ranked #1 on the ST Top 25 R2K List. 

On Thursday, CEO Stanley Erck announced that Novavax intends to file for U.S. approval of its coronavirus vaccine candidate in December.

The YTD chart shows a trend reversal as of late. Can $NVAX stop the bleeding in Week #36? Place your bets…

$NVAX is up 2,600% YTD.

▼ #2 R2K – Vaxart didn’t fare any better than its ST Top 25 R2K Rival, Novovax. The stock fell every single day this week and closed down 24%. It has fallen 9 out of the last 10 days, no bueno. Still, it’s ranked #2 on the list.

About the only positive thing that happened to the company this week was the appointment of Karen J. Wilson to its Board of Directors and as chair of its Audit Committee. Karen has 3+ decades of finance and leadership experience in the life sciences industry.

Vaxart Ceo, Andrei Floroiu, had this to say:

We welcome Ms. Wilson to the Board of Directors. She joins us at an exciting time for our company as we advance our oral COVID-19 vaccine candidate towards the clinic. Her expertise in finance and operations in the biopharmaceutical industry will be an asset to Vaxart’s growth as we are developing vaccines that provide broad immunity for patients while creating value for our stakeholders.

We wish you the best of luck, Ms. Wilson.

See Y’all Next Week.